Search Results
May 07, 2026, 07:36 ET PAN GLOBAL CONFIRMA ALTA LEY EN SUPERFICIE CON 5,0 METROS A 20,2 g/t DE ORO EN EL PROYECTO CÁRMENES
análisis de oro, platino y paladio se realizaron mediante ensayo al fuego de 50 g con acabado ICP-AES (PGM-ICP24). El análisis multielemental se llevó a cabo mediante digestión con 4 ácidos y acabado ICP-AES (ME-ICP61). Las muestras con contenido de oro superior al límite de determinación se analizaron
More news about: Pan Global Resources Inc.
May 07, 2026, 07:27 ET PAN GLOBAL REPORTS SURFACE HIGH-GRADE GOLD WITH 20.2 g/t OVER 5.0 METERS AT CÁRMENES PROJECT, SPAIN
methods CRU-31, SPL-22Y and PUL-31. Gold, platinum and palladium analyses were by 50g Fire Assay – ICP-AES finish (PGM-ICP24). Multi element analysis was undertaken using a 4-acid digest with ICP-AES finish (ME-ICP61). Over-grade gold samples were analyzed using Fire Assay with Gravity Finish (Au-GRA21).
More news about: Pan Global Resources Inc.
May 07, 2026, 07:27 ET PAN GLOBAL REPORTS SURFACE HIGH-GRADE GOLD WITH 20.2 g/t OVER 5.0 METERS AT CÁRMENES PROJECT, SPAIN
methods CRU-31, SPL-22Y and PUL-31. Gold, platinum and palladium analyses were by 50g Fire Assay – ICP-AES finish (PGM-ICP24). Multi element analysis was undertaken using a 4-acid digest with ICP-AES finish (ME-ICP61). Over-grade gold samples were analyzed using Fire Assay with Gravity Finish (Au-GRA21).
More news about: Pan Global Resources Inc.
May 06, 2026, 12:10 ET 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
becomes one of the critical factors in product evaluation. Across different dose levels of BGM0504, treatment discontinuation due to adverse events (AEs) can more directly reflect the drug's sustainable use capability in real-world settings.
More news about: BrightGene
May 06, 2026, 09:25 ET Industry Leaders Demonstrate Integrated Post-Quantum Security Solutions at OFC 2026
quantum-secured communications at OFC 2026, showcasing a layered security architecture that integrates quantum key distribution, quantum authentication, and AES-256-GCM optical encryption. The solution addresses both current cybersecurity threats and future risks posed by quantum computers by combining optical-layer
More news about: Equity Insider
May 06, 2026, 08:00 ET Crystal Instruments Launches Ruby Wireless Vibration Sensor with High Accuracy and 36-Month Battery Life
industrial wireless standard with self-organizing mesh networking, the Ruby enables hundreds of sensors to be deployed across a single facility with AES-128 encryption and FIPS 140-2 compliant security.
More news about: Crystal Instruments
May 05, 2026, 14:40 ET WinMagic Achieves FIPS 140-3 Validation, Continuing 24 Years of Unbroken Cryptographic Certification as Identity Moves to the Endpoint
FORTEZZA PC-card. The first disk encryption certified by the NSA for US Government agencies to SECRET level.March 2002 — AES Certificate #1. The first AES algorithm validation issued by NIST to any commercial vendor. The implementation was the SecureDoc Cryptographic Engine.May
More news about: WinMagic
Apr 30, 2026, 09:53 ET Verified Clinical Trials und Chubb geben strategische Allianz zur Förderung der Sicherheit von Studienteilnehmern, der Datenqualität und des Erfolgs klinischer Studien bekannt
Innovatoren bis hin zu einigen der weltweit größten Unternehmen. Chubb-Kunden können von einer zusätzlichen Schutzebene gegen unerwünschte Ereignisse (AEs), schwerwiegende unerwünschte Ereignisse (SAEs), Prüfplanabweichungen und beeinträchtigte Datenqualität profitieren, die mit doppelten oder nicht offengelegten
More news about: Verified Clinical Trials LLC
Apr 29, 2026, 08:31 ET Apricorn Appoints Jeanclaude Toma as Chief Executive Officer
reliability, and ease of deployment are essential.About ApricornApricorn develops and provides software-free, quantum-resistant 256-bit AES XTS hardware-encrypted storage platforms designed to protect data at rest and enable its secure portability. For more than four decades, Apricorn has
More news about: Apricorn
Apr 28, 2026, 10:27 ET Verified Clinical Trials and Chubb Announce Strategic Alliance to Advance Research Subject Safety, Data Quality, and Clinical Trial Success
from emerging innovators to some of the largest in the world. Chubb clients can benefit from an additional layer of protection against adverse events (AEs), serious adverse events (SAEs), protocol deviations, and compromised data quality associated with duplicate or undisclosed study participation.By
More news about: Verified Clinical Trials LLC
Apr 28, 2026, 10:12 ET Verified Clinical Trials and Chubb Announce Strategic Alliance to Advance Research Subject Safety, Data Quality, and Clinical Trial Success
from emerging innovators to some of the largest in the world. Chubb clients can benefit from an additional layer of protection against adverse events (AEs), serious adverse events (SAEs), protocol deviations, and compromised data quality associated with duplicate or undisclosed study participation.By
More news about: Verified Clinical Trials LLC
Apr 28, 2026, 09:00 ET Actian Launches VectorAI DB with 22x Faster Vector Search for Production AI Anywhere, Including the Edge
environments.Government agencies where sensitive data must remain within classified environments and under full organizational control.The database includes AES-256 encryption and support for customer-managed API keys. It supports deployment configurations aligned with HIPAA, GDPR, ISO 27001, and SOC 2 Type II
More news about: Actian
Apr 28, 2026, 00:00 ET Switchを大画面に簡単接続 ----HAILESI S123E、日本のポータブルモニター市場に登場 Amazon日本売上ランキングTOP5入り
ます。さらに、100％sRGBの広色域、300ニットの高輝度に対応し、HDR機能も搭載。臨場感のある自然な視聴体験を提供します。タッチ操作機能も大きな魅力です。S123Eはフルラミネーションタッチパネルを採用し、AES1.0/2.0スタイラスペンに対応。精密な筆記とスムーズな操作を実現し、ノート作成やイラスト制作など多様なシーンで活用できます。OTG機能の搭載により、キーボードやマウスを直接接続し、簡単にモバイルオフィス環境を構築できます。設計面では、軽量で持ち運びやすさと実用性を両立し、本体一体型スタンドにより角度調整も自在です。内蔵デュアルスピーカーにより日常の
More news about: HAILESI
Apr 27, 2026, 13:30 ET AES Cleanroom Technology appoints John Groth as Chief Revenue Officer
don't reach patients on time," Groth said. "AES has spent 40 years earning trust in this market. My focus is converting that trust into growth by tightening how we sell, design, and deliver as one team."About AES Cleanroom TechnologyAES Cleanroom Technology is a full-service modular
More news about: AES Cleanroom Technology
Apr 23, 2026, 08:54 ET Apricorn Expands Aegis Padlock DT FIPS Line with New 32TB Capacity
https://apricorn.com/aegis-padlock-dt-fips.About ApricornApricorn develops and provides software-free, quantum-resistant 256-bit AES XTS hardware-encrypted storage platforms designed to protect data at rest and enable its secure portability. For more than four decades, Apricorn has
More news about: Apricorn
Apr 22, 2026, 07:30 ET BTQ Technologies Appoints Dr. Gopikrishnan Muraleedharan as Head of Quantum Algorithm and Applications Research, Advances Sydney Operations and Global Quantum Initiatives
productization. Validated FPGA IP is currently available to early partners, ASIC IP performance estimates for ML-KEM, ML-DSA, SHA-3, and AES are targeted for Q2 2026, and development boards for QCIM IP are expected to debut in Q3 2026. BTQ's 13-person QCIM engineering team is now nearly complete,
More news about: BTQ Technologies Corp.
Apr 22, 2026, 02:11 ET EQT AB (publ) Q1 Announcement 2026
addition, EQT provided co-investment opportunities of €4bn for its clientsInvestments include the public tender offer of clean energy platform AES in North America, the acquisition of waste management provider Urbaser in Europe (Infrastructure VI) and the investment in UK-based provider of critical
More news about: EQT
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
IBTROZI, consistent with its prescribing information. Adverse events (AEs) of clinical interest (diarrhea, nausea, vomiting and dizziness) were generally low-grade and resolved quickly. Treatment discontinuations due to treatment-emergent AEs (TEAEs) were low (8.5%). No new safety signals were identified with
More news about: Nuvation Bio Inc.
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Characterization andmanagement ofgastrointestinal (GI)adverse events (AEs)with zanidatamab +chemotherapy (CT) ±tislelizumab in first-line(1L) HER2-positive(HER2+) locallyadvanced
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 12:40 ET Five Hoxhunt Customers Win Prestigious CSO Awards for Innovation in Human Risk Management
Qualcomm, Docusign, Nokia, AES, Air Asia, and E.on, and partners with leading global cybersecurity companies such as Microsoft and Deloitte.Media ContactChristian
More news about: Hoxhunt
Apr 20, 2026, 09:51 ET COURTNEY LEMARCO, EXECUTIVE PRODUCER AND SHOWRUNNER OF A&E'S "HOARDERS," DEVELOPS PROVOCATIVE NEW UNSCRIPTED SERIES
multimedia:https://www.prnewswire.com/news-releases/courtney-lemarco-executive-producer-and-showrunner-of-aes-hoarders-develops-provocative-new-unscripted-series-302747310.htmlSOURCE
More news about: The LeMarco Group
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
observed. Treatment-related adverse events (AEs) occurred in 83.5% of patients who received LU-AT, compared with 40% in the AT arm. This variation was observed in patients who experienced a grade 3/4 AE (25.6% vs. 5.8%), a grade 5 AE (0.8% vs. 0.4%) and AEs that led to treatment discontinuation (6.2%
More news about: Specialised Therapeutics
Apr 17, 2026, 16:01 ET Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
Endevica Bio and is currently being administered by Kalohexis. Primary endpoints include change from baseline in body weight, incidence and severity of AEs, and incidence of lab or vital sign abnormalities; secondary endpoints include change from baseline in appetite and quality of life.Poster
More news about: Kalohexis
Apr 16, 2026, 11:03 ET /C O R R E C T I O N -- Boehringer Ingelheim/
(mDoR) was 15.2 months, and the median progression free survival (mPFS) was 14.4 months.Treatment-related adverse events (AEs) were predominantly low-grade. AEs led to dose reductions in 12 patients (16%) and dose discontinuations in 7 patients (9%).Additionally, the NEJM manuscript
More news about: Boehringer Ingelheim
Apr 16, 2026, 08:48 ET XPENG Maintains MSCI ESG AAA Rating, Advances Carbon Reduction and Responsible AI in 2025 ESG Report
real-world outcomes.Its advanced driver assistance technologies, including Automatic Emergency Braking (AEB) and Automatic Emergency Steering (AES), enable proactive risk detection and intervention, helping to avoid more than 376,000 potential collision risks, according to internal system data.The
More news about: XPENG